Leroy Vaughan, MD
Internal Medicine · Richmond, VANPI 1366646697
Payments from drug & device makers
Across 8,057 payments — averaging $2586.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$14.3M
- Pfizer$5.6M
- Novavax Inc$570K
- Seqirus USA Inc$295K
- AbbVie$54K
- AstraZeneca$5K
- plus $438 from 11 others
Across 4 payments — averaging $335.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novavax Inc$1K
What the payments were for
- Speaking & faculty fees$51,75094%
- Travel & lodging$8562%
- Food & beverage$2,3474%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 7,659 | $14,288,074 |
| Pfizer | 141 | $5,631,551 |
| Novavax Inc | 45 | $569,925 |
| Seqirus USA Inc | 144 | $294,548 |
| AbbVie | 52 | $54,208 |
| AstraZeneca | 1 | $4,600 |
| Ferring Pharmaceuticals Inc. | 3 | $187 |
| Melinta Therapeutics, LLC | 3 | $77 |
| Grifols USA, LLC | 1 | $27 |
| La Jolla Pharmaceutical Company | 1 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Sanofi | 1 | $18 |
| Merck | 1 | $18 |
| Amgen | 1 | $18 |
| Cumberland Pharmaceuticals, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,843,345 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fosfomycin Tromethamine | 30 | $6,119 |
| Cefaclor | 14 | $1,645 |
| Cephalexin | 46 | $733 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $573 |
| Ciprofloxacin Hcl | 23 | $281 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 20 | $217 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Richmond
- Andrew PoklepovicRichmond$4.6M
- Richard JacksonRichmond$2.5M
- Lawrence SchwartzRichmond$2.4M
- John HoekstraRichmond$344K
- Franklin ZieveRichmond$337K
- Wally SmithRichmond$333K
- Thokozeni LipatoRichmond$247K
- John BarrettRichmond$217K
- Alan DowRichmond$156K
- Sherman BakerRichmond$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.